Veeva Adds New Capabilities to Veeva Site Connect
Latest version offers a streamlined site-centric experience to simplify relationships with study sponsors.
Veeva Systems has announced the newest release of Veeva Site Connect. New capabilities of the solution are headlined by a streamlined site-centric experience that will simplify and standardize site-sponsor relationships.1
The solution offers sponsors and sites a single place to collaborate, automating information flow throughout the lifecycle of a clinical trial. Information flow includes protocols, safety reports, payment letters, and more.
New features of Veeva Site Connect include:
- Expansion beyond document exchange and safety distribution: Veeva Site Connect adds study communications, contacts, payment information, and quick links to sponsor systems to document exchange and safety distribution capabilities.
- Optimized site user interface that’s the same for all trials: Organizing everything sites need in an intuitive site homepage with simple sidebar navigation.
- Accessible for all sites everywhere.
- Simple fixed price implementation to get up and running in two to four months.
“By standardizing how information is shared across all sites in one application with Veeva Site Connect, we aim to save time and effort that can be focused on treating patients,” a clinical operations excellence leader at a top 20 biopharma said in a press release. “Our goal is to eliminate manual handoffs and inefficiencies for faster site start-up, more efficient monitoring, and simplified study closeout.”
Veeva Site Connect is part of Veeva Clinical Platform, which is the provider’s complete solution for patients, sites, and sponsors. According to Veeva, seven of the top 20 biopharmas have already adopted Site Connect.
“I would be ecstatic if all our sponsors use Veeva Site Connect. It gives sites a much more efficient way to collaborate with sponsors, maintain regulatory compliance, and get critical therapies to patients faster,” Alisha Garibaldi, CEO, Skylight Health Research, said in the press release. “The less time we spend doing administrative work in systems, the more time we have to execute trials and help patients.”
Marta Jureczko-Hinzmann, head of global clinical solution services at AstraZeneca added, “By implementing Veeva Site Connect for our safety letter distribution process, we anticipate achieving a significant reduction in manual processing while enhancing oversight and compliance. Sharing safety letters across all sites globally within a single application will allow us to harmonize the entire process across the company and optimize how we allocate valuable resources.”
This announcement from Veeva comes just days before its R&D Quality Summit which will be taking place in Boston, MA, September 9-10.
Reference
1. Major Release of Veeva Site Connect Streamlines Clinical Trial Execution for Sites and Sponsors. News release. Veeva Systems. September 5, 2024. Accessed September 5, 2024. https://www.veeva.com/resources/major-release-of-veeva-site-connect-streamlines-clinical-trial-execution-for-sites-and-sponsors/
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FSP Outsourcing in Clinical Research: Trends and Opportunities
June 9th 2025When drug developers choose the right outsourcing strategies in clinical research, they can gain significant benefits in terms of quality, efficiency, and operational success. In its third annual Functional Service Provider (FSP) Trends Report, Thermo Fisher Scientific’s clinical research business—PPD—gathered insights from 150 global biotech and pharma leaders to determine how FSP models help sponsors address common industry obstacles.
